Navigation Links
Vion Pharmaceuticals Reports 2009 First Quarter Results

Company to hold Conference Call on May 14, 2009

NEW HAVEN, Conn., May 11 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced financial results for the first quarter of 2009.

The Company reported a net loss of $4.3 million, or $0.54 per share, for the quarter ended March 31, 2009, compared with a net loss of $8.2 million, or $1.14 per share, for the same 2008 period. Weighted-average common shares outstanding for the three months ended March 31, 2009 and March 31, 2008 were 7.9 million and 7.2 million, respectively.

The Company reported ending the quarter with $30.0 million in cash and cash equivalents. Based on its current operating plan, management estimates that its existing cash and cash equivalents will be sufficient to fund operations through the first quarter of 2010.

In February 2009, the Company submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its lead anticancer agent Onrigin (laromustine) Injection for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). In April 2009, the Company announced that the FDA had accepted the NDA for review and that it had been assigned an end user fee date of December 12, 2009 for a decision on approval by the FDA.

Alan Kessman, Chief Executive Officer, commented, "We are continuing to interact with the FDA on our NDA with the objective of receiving approval for Onrigin in its first indication in the U.S. by the end of 2009."

Conference Call

The Company will hold a conference call at 8:30 a.m. Eastern Time on May 14, 2009 to discuss its operations and financial results.

To participate in the conference call, please dial (866) 271-6130 in the U.S. ((617) 213-8894 for international callers) at least 15 minutes before the start of the call. When prompted for a pass code, please enter 50015632.

An audio webcast of the call will be accessible at Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 82833471. The replay will be available through Thursday, May 28, 2009.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin (laromustine) Injection and Triapine(R). The Company has an NDA under review with the FDA for Onrigin for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin (laromustine) Injection, delays in the regulatory approval process, particularly for Onrigin (laromustine) Injection, including possible delays in the FDA's review process beyond our expectation for approval in December 2009, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2008, and "Risk Factors" in Vion's Post-Effective Amendments on Form S-1 Registration Statement filed on March 23, 2009. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    COMPANY CONTACT:         Vion Pharmaceuticals, Inc.
                             Alan Kessman, Chief Executive Officer
                             Howard B. Johnson, President & CFO
                             (203) 498-4210

                             VION PHARMACEUTICALS, INC.
                           (A Development Stage Company)


                                                     Three Months Ended
                                                          March 31,
    (In thousands, except per share data)          2009              2008

    Technology license fee revenue                   $5               $14

    Operating expenses:
         Clinical trials                          1,021             2,854
         Other research and development           1,980             2,259
             Total research and development       3,001             5,113
         Marketing, general and administrative    1,616             2,087
            Total operating expenses              4,617             7,200

    Loss from operations                         (4,612)           (7,186)

         Interest income                              7               502
         Interest expense                        (2,344)           (1,505)
         Other income (expense), net              2,652               (6)
    Loss before income taxes                     (4,297)           (8,195)

         Income tax provision (benefit)              --                --
    Net loss                                    ($4,297)          ($8,195)

    Basic and diluted loss per share(1)          ($0.54)           ($1.14)

    Weighted-average number of shares
     of common stock outstanding(1)               7,944             7,173

    (1) Adjusted for all periods presented to reflect the Company's
        one-for-ten reverse stock split effected February 20, 2008.


                                                 Mar 31,           Dec 31,
    (In thousands)                                 2009              2008

    Cash and cash equivalents                   $29,958           $37,990
    Total assets                                 31,240            39,474
    Convertible senior notes                     54,156            55,443
    Total liabilities                            59,050            62,858
    Shareholders' deficit                       (27,810)          (23,384)

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
2. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
3. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Photos: Generic Pharmaceuticals Saved $734 Billion over Last Decade
5. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
6. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
8. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
9. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
10. Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Ferring Pharmaceuticals and RESOLVE: The National Infertility Association Join Together to Launch Nurse Liaison Program
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... A team of Swiss doctors has released a report on ... just posted the findings on the website. Click here to read the details ... mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the 106 ...
(Date:11/27/2015)... ... ... Lizzie’s Lice Pickers just announced a special promotion that will run throughout ... of lice treatment product. In addition, customers will receive a complimentary head Check when ... is a sure way to ruin the holidays, so we encourage all of our ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that ... ). More than 3.7 billion people under the age of 50 – or 67% ... WHO's first global estimates of HSV-1 infection . , "The data shocks us highly!" ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the German Drugs ...
Breaking Medicine Technology: